No discrete molecular target

Assets acting on this target.

Class
No single molecular target (whole-cell, viral, gene or multi-component therapy)
Pathway
innate-like γδ T-cell-mediated tumor cytotoxicity, primed by localized low-dose radiation
Notes
original target text: not a molecular receptor target -- allogeneic donor-derived cell product

This therapy is not built around a single molecular receptor or enzyme. Instead, it uses an entire immune cell type, gamma-delta (γδ) T cells, manufactured from a donor (allogeneic) rather than the patient, and delivered alongside localized low-dose radiotherapy to the tumor site. γδ T cells are a minority subset of T lymphocytes that recognize stressed or transformed cells through mechanisms that do not require matching the patient's own tissue markers (major histocompatibility complex, or MHC), unlike conventional T cells. This property makes them naturally suited to an 'off-the-shelf' allogeneic product, since they carry lower risk of attacking healthy host tissue or being rapidly rejected. Low-dose radiation is used not to directly kill the tumor but to alter it biologically: radiation-stressed tumor cells display more of the molecular flags that γδ T cells detect, and radiation can also loosen the local immunosuppressive environment that otherwise shields tumors from immune attack. Combining a donor-derived innate-like effector cell with a radiation 'priming' step is a strategy relevant across solid tumor types where immune cells struggle to recognize and penetrate tumor tissue. The general rationale extends to broader efforts in cellular immuno-oncology and combination approaches pairing cell therapies with conventional oncologic modalities.

By indication

No discrete molecular target drugs compared

8 drugs, stage by indication
8 drugs acting on No discrete molecular target: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Vusolimogene oderparepvec (Tudriqev)TudriqevReplimune, Inc.oncolytic virusApprovedApproved in Melanoma; Phase 2 in Non-Small Cell Lung Cancer
Olvimulogene nanivacirepvecGenelux Corporation, Newsoara HYK Biopharmaceuticals Co., Ltd.oncolytic virusPhase 3Phase 3 in Ovarian Cancer; Phase 2 in Non-Small Cell Lung Cancer
LN-145Iovance Biotherapeuticscell therapyPhase 2Phase 2 in Non-Small Cell Lung Cancer
Adipose-derived MSC clusters (S.Biomedics)S.Biomedicscell therapy (allogeneic adipose-derived MSC)Phase 1/2Phase 1/2 in Atherosclerotic Cardiovascular Disease
BGC101BioGenCellcell therapy (autologous endothelial progenitor cells)Phase 1/2Phase 1/2 in Atherosclerotic Cardiovascular Disease
SL-28Second Life Therapeuticscell therapyPhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
ALF202Allife Medical Science and Technologycell therapy (iPSC-derived endothelial progenitor cells)Phase 1Phase 1 in Atherosclerotic Cardiovascular Disease
KB-GDT-01Immunocell Therapeutics, Inc.cell therapyPhase 1Phase 1 in Non-Small Cell Lung Cancer

← all mechanisms